Scarica l'app Stockscreener
1.31
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.31
Aprire:
$1.31
Volume 24 ore:
1.10M
Relative Volume:
0.46
Capitalizzazione di mercato:
$547.40M
Reddito:
$1.21M
Utile/perdita netta:
$-177.12M
Rapporto P/E:
-1.6375
EPS:
-0.8
Flusso di cassa netto:
$-162.37M
1 W Prestazione:
+6.50%
1M Prestazione:
+9.17%
6M Prestazione:
+18.02%
1 anno Prestazione:
+76.72%
Intervallo 1D:
$1.28
$1.35
Intervallo di 1 settimana:
$1.17
$1.385
Portata 52W:
$0.2836
$1.83
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Nome
Lexicon Pharmaceuticals Inc
Settore
Industria
Telefono
(281) 863-3000
Indirizzo
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.31 | 547.40M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-30 | Iniziato | Leerink Partners | Outperform |
| 2023-03-07 | Iniziato | Jefferies | Hold |
| 2022-08-12 | Iniziato | Piper Sandler | Overweight |
| 2021-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-18 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Downgrade | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Downgrade | Stifel | Buy → Hold |
| 2019-03-25 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Reiterato | Stifel | Buy |
| 2018-02-23 | Downgrade | Needham | Buy → Hold |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Reiterato | H.C. Wainwright | Buy |
| 2017-03-01 | Reiterato | Wedbush | Outperform |
| 2016-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-05 | Reiterato | Wedbush | Outperform |
| 2016-08-02 | Iniziato | Citigroup | Buy |
| 2016-03-02 | Reiterato | Wedbush | Outperform |
| 2015-11-09 | Reiterato | Wedbush | Outperform |
| 2015-09-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Downgrade | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
How rising interest rates impact Lexicon Pharmaceuticals Inc. stock2025 Analyst Calls & Free Daily Entry Point Trade Alerts - mfd.ru
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Sentiment Recap: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaTrade Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Lexicon Pharmaceuticals completes $100 million stock offering By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals completes $100 million stock offering - Investing.com
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - The Manila Times
Lexicon Pharmaceuticals Completes Public Offering of Common Stock and Concurrent Private Placement - Quiver Quantitative
Lexicon raises about $94.6M to fund drug work and operations - Stock Titan
Lexicon Pharmaceuticals prices $94.6M share offering - MSN
Insider Buying: Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Acquires 1,538,462 Shares of Stock - MarketBeat
Market Review: How does Lexicon Pharmaceuticals Inc compare to its peersWeekly Market Outlook & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing - The Globe and Mail
Lexicon Pharmaceuticals Signs Multiple Material Agreements - TradingView
FOMO Trade: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteria2025 Momentum Check & Capital Protection Trade Alerts - baoquankhu1.vn
Lexicon Pharmaceuticals Initiates Stock Offering to Drive R&D Growth - StocksToTrade
Lexicon Pharmaceuticals Stock Offering: Strategic Move to Boost R&D - timothysykes.com
Pullback Watch: Can Lexicon Pharmaceuticals Inc reach all time highs this yearWeekly Trading Summary & Technical Pattern Alert System - baoquankhu1.vn
Lexicon Pharmaceuticals Announces Key Stock Offering amid Strategic Funding Efforts - StocksToTrade
Lexicon Pharmaceuticals prices public offering at $1.30 per share By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals launches public offering of common stock By Investing.com - Investing.com Australia
Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones - Finviz
Lexicon Pharmaceuticals stock tumbles on public offering pricing By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Engages Jefferies and Piper Sandl - GuruFocus
Lexicon Pharmaceuticals stock tumbles on public offering pricing - Investing.com India
Lexicon Pharmaceuticals (LXRX) Raises $41.6M Through Public Offe - GuruFocus
Lexicon Pharmaceuticals prices public offering at $1.30 per share - Investing.com
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - The Manila Times
Lexicon announces pricing of approximately $94.6 million public offering at $1.30 per share - marketscreener.com
Drug developer Lexicon raises $94.6M to fund pipeline and operations - stocktitan.net
Lexicon Pharmaceuticals (LXRX) Initiates Public Stock Offering - GuruFocus
Lexicon Pharmaceuticals (LXRX) Launches Public Offering, Shares Dip - GuruFocus
Lexicon Pharmaceuticals launches public offering of common stock - Investing.com
Lexicon Announces Proposed Public Offering of Common Stock - The Manila Times
Lexicon (NASDAQ: LXRX) plans stock sale, highlights late-stage pipeline - stocktitan.net
Lexicon plans stock sale to fund drug candidate research, operations - Stock Titan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 8.5%Should You Sell? - MarketBeat
Lexicon Pharmaceuticals Rings the Closing Bell - Nasdaq
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) - Yahoo Finance
Risk Report: Can Lexicon Pharmaceuticals Inc reach all time highs this year - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Lexicon Pharma spikes after FDA feedback on pain drug - MSN
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends - ChartMill
Lexicon Pharmaceuticals Inc Azioni (LXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):